



(11)

EP 2 270 008 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:

C07D 471/04 (2006.01) **A61K 31/4188** (2006.01)
A61P 35/00 (2006.01) **A61P 29/00** (2006.01)
A61P 11/06 (2006.01)

(48) Corrigendum issued on:

03.04.2013 Bulletin 2013/14

(45) Date of publication and mention
of the grant of the patent:

03.10.2012 Bulletin 2012/40

(21) Application number: 10175375.4

(22) Date of filing: 18.05.2006

(54) **8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors**

8-Heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-on-Verbindungen als PI-3 kinase Hemmer
 8-Hétéroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones comme inhibiteurs des PI-3 kinases

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
 HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
 SK TR**

Designated Extension States:

AL BA HR MK YU

(30) Priority: 20.05.2005 GB 0510390

(43) Date of publication of application:

05.01.2011 Bulletin 2011/01

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:**06753710.0 / 1 888 578**(73) Proprietor: **Novartis AG**
4056 Basel (CH)

(72) Inventors:

- Garcia-Echeverria, Carlos**
4052, Basel (CH)

- Stauffer, Frédéric**
4153, Reinach (CH)
- Furet, Pascal**
F-68800, Thann (FR)

(74) Representative: **Gruber, Markus et al**
Novartis Pharma AG
Patent Department
4002 Basel (CH)

(56) References cited:
WO-A1-2005/054237 **WO-A1-2005/054238**
WO-A2-03/097641

Remarks:

The file contains technical information submitted after
the application was filed and not included in this
specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).